Summary The crucial role of non-plasminogen dependent serine proteinases is tissue invasive and cytolytic functions of Walker 256 cancer cells has been documented using a rat urinary bladder invasion and a 1251_ labelled fibroblast cytolysis assay. The invasive capacity of these cancer cells was abrogated by non toxic concentrations of the serine proteinase inhibitors, diisopropylfluorophosphate and phenylmethylsulfonylfluoride, but not by metallo or cysteine proteinase inhibitors. Although tumour cell collagenase activity and plasminogen activator were demonstrated, these proteolytic enzymes were not essential in these in vitro assays. These results suggest that different categories of proteinases play specific roles in the complicated process of cancer invasion.
The capacity of malignant cells to invade surrounding normal structures at both the primary and metastatic organ sites is of central importance in the dissemination of cancer Nicholson, 1979) . Serine, cysteine and metalloproteinases have independently been implicated as important enzymes in cancer invasion (Barrett, 1980) . A dearth of experimental models has been a limiting factor in understanding the role of specific enzymes in cancer invasion. The purpose of this report is to describe recently developed experimental assay systems that we have used to characterize the essential role of cancer cell proteinases in tissue penetration and parenchymal cell damage. Using pharmacologic agents, we have identified the importance of each category of proteinases in the highly invasive Walker 256 (W-256) cancer cell line. Although both serine and metalloproteinases were identified and often enriched in W-256 tumour cell membranes, the non-plasminogen dependent serine proteinase(s) appeared to play the more crucial role in parenchymal cell and tissue destructive effects of cancer.
Materials and methods
RPMI 1640 was obtained from Flow Laboratories, McLean, VA, N-a-P-tosyl-L-lysine chloromethyl ketone (TLCK), diisopropylfluorophosphate (DFP), soybean trypsin inhibitor (SBTI), N-ethylmaleimide (NEM), Trypsin-TPCK, phenylmethanesulfonylfluoride (PMSF), and 1, 10 phenanthroline Male Wistar rats were used throughout. Walker 256 (W-256) carcinosarcoma, obtained from Arthur D. Little Co., Boston, MA, were serially transplanted as a highly invasive ascitic tumour and were isolated free of contaminating cells on FicollHypaque as previously described (Zucker & Lysik, 1977; . L-929 fibroblasts, obtained from Flow Laboratories, were propagated in vitro in RPMI-1640 +10% heat-inactivated foetal calf serum. All cells were washed three times in RPMI-1640 to remove all serum components prior to study.
Radiolabelling of cells L-929 fibroblasts (106 ml-1) were radiolabelled in vitro with 0.5 juCi 125I-5' iodo-2 deoxyuridine for 24 h. Fibroblasts were then collected by trypsinization, washed thoroughly, and used as a single cell suspension. W-256 cancer cells were radiolabelled in vivo by injecting 1O0Ci of 125I-UdR i.p. into ascitesbearing rats 24 h prior to sacrifice (day 6 after tumour transplantation) and then harvested and prepared for assays as described above. This radio-labelling procedure did not alter the invasive or cytolytic capacity of W-256 cells.
Tumour-induced fibroblast lysis assay
To provide a better model of cancer cell:normal cell interactions occuring during tumour cell invasion of most parenchymal organs, we have now modified the tumour-induced erythroid cytolysis assay . Drug-induced inhibition of cytolysis was calculated using the mean of the release index (RI). Effect of pharmacologic agents on cancer cell and fibroblast viability The viability of drug-treated cancer cells and fibroblasts was ascertained by measuring tumour colony formation in methyl cellulose (>8 cells per colony) after 3 days of cell incubation in the presence of drugs (Zucker et al., 1980) , and the 3 day incorporation of 3H-thymidine and '4C-leucine into tumour cell and fibroblast DNA and protein, respectively, as previously described . Drug concentrations resulting in <80% cell viability as determined by trypan blue dye exclusion were excluded from further study.
Bladder invasion assay
In our modification of the urinary bladder invasion assay, described originally by Hart (1979) , male rats were killed and the peritoneal cavity was exposed using asceptic technique. The urinary bladder was emptied of its content, and the ureters were tied off.
A 0.5 ml suspension of '25I-UdR labelled or unlabelled W-256 or L929 cells (2x 106 m -1) was injected into the urinary bladder by retrograde flow through the urethra. A urethral ligature was then tightened. The bladder was then excised, and placed either upright in 10 x 75mm friction cap tubes containing 8 ml of NCTC-135 for radioactive counting or in 35 mm plastic Petri dishes containing a preformed base of 3% methylcellulose in NCTC-135 for colony counting. After 48h of incubation at 37°C in 5% CO2 and 95% air, the bladders were removed from the tubes and radioactivity of the external fluid bathing the bladder and the intact bladder were separately measured in a gamma counter. The overall integrity of the bladder wall was checked by injecting india ink in the bladder lumen . In colony experiments the methyl cellulose embedded bladders were removed after 48 h of incubation and tumour colonies forming in the semisolid media were counted as we have previously described (Zucker et al., 1980) . In various experiments, 125I-labelled or non-labelled W-256 cells were pre-treated with pharmocologic agents for 30 min before injecting the tumour cells into the bladder. Significant differences between groups were calculated by the Student's "t" test.
Assay of plasminogen activator Plasminogen-dependent fibrinolytic activity of W-256 cells and the effects of proteinase inhibitors on cancer cell PA was determined using 3H-fibrinogen (90 pg per plate) clotted with 5% FCS with the addition of human plasminogen (20gml -1) as previously described (Barrett et al., 1977) . W-256 cell homogenates and cell membranes (1 pg samples) were added, with or without pharmacologic agents, and after 18h of incubation at 37°C, the release of 3H by tumour cell fractions was compared to maximum release produced by an excess of urokinase (1 ploug unit=100%).
Assays of collagen degradation
The synthetic peptide P substrate, (2,4 dinitrophenyl) DNP-Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg-OH was employed to quantitatively assay tumour cell collagenase-like activity (Masui et al., 1977 : Grant & Eisen, 1980 125I-UdR labelled L929 fibroblasts (5 x 106) were mixed with 5 x 106 W-256 cancer cells suspended in 1 ml of RPMI-1640 (without foetal calf serum) and incubated at 37°C for 1, 2 and 3 days. The cultures were terminated by centrifugation and the radioactivity in the supernate and pellet were measured. Fibroblast lysis (Release Index) was calculated by comparing 125I in the supernate to total 125I (supernate and pellet). All samples were run in triplicate and reported as the mean±s.d. The 72h experiment included a concurrent incubation of W-256 cancer cells with the proteinase inhibitors DFP (10-3M), PMSF (2x 10-4M), EACA (2x 10-3M), Cu+I (10 -3), 1,10 phenanthroline (10-3 M) and the inhibitor of protein synthesis, emetine (10-4 M). These drugs alone did not increase the baseline 125I1 Fibroblast release. spectrum serine proteinase inhibitors), TLCK (active site trypsin-like inhibitor), Cu+ + (nonspecific inhibitor of elastase-like serine and cysteine proteinases) or emetine (an inhibitor of protein synthesis) produced significant inhibition of cancerinduced fibroblast lysis Quigley, 1979; Strauli et al., 1977 , Stevens et al., 1983 Table I .
Walker 256 cell membranes were prepared by hypotonic lysis followed by sucrose density gradient centrifugation and characterized by marker enzyme analysis and electron microscopy as previously described . Walker 256 cell membranes (100igml 1) or intact W-256 cells were incubated with 125I-labelled L929 fibroblasts (5 x 106 ml-l) for 1, 2 or 3 days and fibroblast lysis was measured as noted in Table I . The 72 h experiment included a concurrent incubation of W-256 cell membranes with DFP (I0-3 M) or PMSF (2 x 10-M). These enzyme inhibitors alone did not affect the baseline release of 1251 from fibroblasts. Isolated bladders from male Wistar rats were given injections of 106 viable 125I-UdR labelled W-256 cancer cells that had been preincubated for 30min with non-toxic concentrations of 7 different proteinase inhibitors and emetine. Organ cultures were incubated for 2 days at 37°C after which the bladders were removed from the tubes and radioactivity of the external fluid bathing the bladder (representing cells penetrating the full thickness of the organ) and the intact bladder were separately measured in a gamma counter. 1251 radioactivity associated with the tumour cells which had penetrated through the bladder into the external fluid was expressed as a percentage of the initial total cellular radioactivity (Invasion Index). The results are compiled from 10 different experiments in which buffer treated W-256 cells were compared to 2-3 different proteinase-inhibitor treated tumour cells. The number of bladders tested per treatment group varied between 6 and 20. membrane, fibrous connective tissue stroma and muscle components . In the initial experiments we demonstrated that 40-60% of 125-labelled W-256 cells penetrated the rat urinary bladder during a 48h incubation. By contrast, 2% of alcohol-treated W-256 cells and 8% of 125I-UdRlabelled L929 fibroblasts (a non-invasive cell line) had penetrated the bladder in a 48h period thus supporting the resistance of the urinary bladder to penetration by dead tumour cells or non malignant cells. Pretreatment of W-256 cancer cells with nontoxic concentrations of DFP, PMSF or TLCK inhibited bladder wall penetration by 68%, 31% and 39%, respectively (Table III) . s-amino caproic acid (EACA), Cu+, leupeptin, (an arginine containing peptide analogue inhibitor of serine and cysteine proteinases, especially cathepsin B), and 1, 10 phenanthroline, did not affect W-256 invasion of the bladder. Short-term incubation with emetine inhibited bladder invasion by 23%.
To ascertain whether the passage of 1251 through the urinary bladder represented intact cancer cells with proliferative capacity of 1251 release from damaged cancer cells, we examined the colony forming ability in agar of W-256 cells that had penetrated through the urinary bladder. Two days after instilling 106 cancer cells into the bladder, 406 +31 W-256 colonies were noted in the surrounding semisolid media. Pretreatment of the W-256 cells with DFP resulted in 74+19 colonies per plate which indicated 82% inhibition of invasion. As noted above, DFP alone did not inhibit W-256 colony formation. Based on these pharmacologic experiments, we conclude that W-256 cancer cell serine proteinases are essential for cancer invasion through a urinary bladder.
Plasminogen-dependent fibrinolytic activity of W-256 cancer cells and the effect of various proteinase inhibitors on cancer cell PA was determined in an 18 h assay using 3H-fibrinogen and human plasminogen (Table IV) . As anticipated, W-256 cell membranes and whole cell homogenates were rich in PA activity, which could be abrogated by pretreatment with EACA, DFP, SBTI (soybean protein inhibitor of trypsin-like enzymes), and TLCK. Since EACA, a plasmin antagonist was able to completely inhibit fibrinolysis in this experiment, without affecting bladder invasion (Table III) or fibroblast target lysis (Table I ), it appears that W-256 cancer invasion is unrelated to plasminogen activation. In contrast, the more general serine proteinase inhibitors (DFP, PMSF) were able to inhibit both the fibrinolytic and invasive aspects of W-256 cancer cells. Table I and SBTI (2 x 10-5M) were preincubated with W-256 cell membranes for 30min prior to performing the standard fibrinolytic assay. Trypsin 100 0 0 5 x 10-4M DNP-Peptide P was dissolved in buffer and incubated with an equal volume of tumour cell homogenate, cell membrane (Triton X-100 solubilized), bacterial collagenase, or trypsin. After 18 h the enzyme reaction was stopped and the released DNP-Peptide fragments were determined by measuring the absorbance (OD 365) in the organic layer.
Collagenolytic activity of W-256 cells was assessed using two different approaches. Table V shows that W-256 cell homogenates and isolated cell membranes possess considerable collagenaselike activity, as monitored using the synthetic substrate, Peptide P, without enzyme enrichment in the cell membrane fraction as assessed by specific activity. To determine the category of enzyme(s) mediating this collagenase-like activity, we preincubated W-256 cell membranes with inhibitors of the metallo, serine and cysteine proteinases (Table VI) . The metalloenzyme inhibitors 1,10 phenanthroline, EDTA and dithiothreitol effectively inhibited the hydrolysis of Peptide P (100%, 100% and 70% respectively). The serine proteinase (DFP, PMSF) and cysteine proteinase inhibitors (N-ethylmaleimide, leupeptin) had no significant effect of Peptide P hydrolysis. Since peptidases without collagenase activity can also cleave Peptide P (Gray & Saneli, 1982) , a specific assay for collagenase was performed using soluble Type I 3H-collagen. Walker 256 cells were rich in latent collagenase activity producing 15.9% degradation of substrate mg-' protein with considerable enrichment (6.2 x) in the plasma membrane fraction (99% degration mg-' protein). The metalloenzyme inhibitors, EDTA and 1,10 phenanthroline, produced >90% inhibition of W-256 cell collagenolytic activity. Table I .
The effect of different protease inhibitors on the rate of hydrolysis of Peptide P after an 18 h incubation with W-256 cell membranes (66 pg) was measured as described in Table   V . Pharmacologic agents were preincubated with the tumour cell membranes for 10min before adding the mixture to Peptide P. Tumour cell fractions were activated with trypsin-TPCK, inactivated with SBTI and then incubated at 27°C for 36h with 10pg (3H-methyl) Type I collagen. Undigested collagen was then precipitated by the addition of dioxane and radioactivity in the filtrate containing collagen degradation products was measured. In the absence of trypsin activation, W-256 cell homogenate lacked measurable amounts of collagenase activity.
Minimal collagenase activity was noted in W-256 cell fractions without prior trypsin activation (Table  VII) .
Discussion
The direct interaction between cancer cells and normal cells during the invasive process has been a difficult problem for experimental evaluation (Mareel, 1981) . Taking advantage of the enhanced susceptibility of erythroblasts and red blood cells to experimental lysis, Zucker & Lysik (1977) introduced the tumour-induced erythroid cytolysis assay (TIEC) to assess the capacity of cancer cells to destroy normal host cells. All 13 cancer cell lines tested to date have been capable of lysing normal 59Fe-labelled bone marrow and red blood cells : DiStefano et al., 1983b Stevens et al., 1983) . Using highly invasive W-256 rat cancer cells, DiStefano et al. (1983b) were able to localize and identify serine proteinases in the cancer cell membrane that were responsible for the lysis of normal erythroid cells. One of these W-256 membrane enzymes, Memsin, has been purified and characterized as a highly active trypsin-like serine proteinase (LaBombardi et al., 1983 . By contrast, the cytolysis inhibitory effect of emetine is probably due to the profound inhibition of tumour protein synthesis, presumably the cytolytic proteinases. Finally, we cannot exclude the possibility that the inhibition of fibroblast lysis produced by copper may be due to a toxic effect on tumour cells. A propos of our work, Sakiyama et al. (1984) have shown that metastatic cancer cells can solubilize and phagocytose fixed cells by a plasminogendependent cell contact requiring phenonemon. Cancer cell attack of fixed cells was abrogated by inhibitors of trypsin-like proteinases, suggesting that the degredation of target cell proteins is a serine proteinase requiring phenomenon. To evaluate invasiveness through tissue components of an intact organ, we examined the penetration by cancer cells of an isolated rat urinary bladder over a 2 day period. In the reports by Hart (1979) and using a mouse urinary bladder and variant melanoma cell lines, a 7 day period was required for tumour cell penetration of the bladder. By contrast, rat W-256 cancer cells were highly invasive of a rat urinary bladder in a 2 day period. Using different categories of proteinase inhibitors we showed that bladder invasion required non plasminogen dependent serine proteinases, which is consistent with our data in the fibroblast lysis assay. Explanations for the effects of proteinase inhibitors on cancer cells other than a direct action on invasive enzymes cannot be excluded. Pharmacologic inhibition of cancer cell motility or aspects of invasion other than tissue destruction need to be considered.
In these experimients we confirmed that W-256 cancer cells possess metalloenzymes with type I collagenolytic activity (Wolf & Wirl, 1982 (Recklies et al., 1982; Sloane et al., 1981; Pietra & Roberts, 1981) . We have found that although W-256 cancer cells have cysteine proteinase activity (data not shown), the inhibition of this category of proteinases by leupeptin had no effect on the in vitro invasion assays that we employed here.
These studies reemphasize the extreme biological variability of cancer in that an individual cancer cell may contain several types of proteinases which may or may not correlate with metastatic potential. Recently Lowe & Isaacs (1984) reported that prostatic cancer cell lines of low and high metastatic potential possess a large array of proteinases with no single enzyme activity correlating with metastatic potential.
To date, the goal of most investigations has been to determine a correlation between a category of cancer proteins (hydrolytic enzymes, surface glycoproteins, etc.) and metastatic or invasive potential of cancer cell lines. In this study we have shown that pharmacologic agents can be used to better characterize the role of specific proteinases in experimental models that examine various factors involved in cancer invasion and normal cell destruction in vitro. The potential use of proteinase inhibitors in the treatment of cancer has not yet been systematically explored (Nelles & Schnebli, 1982) . Our report suggests that the selection of enzyme inhibitors for future in vivo testing should be based on in vitro assays using the specific cancer cell line to be evaluated.
